Results 61 - 70 of 1085 : Previous 3 4 5 6 7 8 9 10 11 Next
Taking the Drug Industry's Temperature
Covance and Icon hint at broader pharmaceutical R&D trends.
Swine Flu Doesn't Need to Save Novartis
The company is looking healthy all on its own.
I Don't Need No Massive Merger
Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
Merck-Schering Doesn't Look So Good
Revenue is stagnant; let's hope that pipeline pans out.
Not 50% Growth, but We'll Take It
Double-digit growth is still pretty good.
The Right Place to Start Investing Now
Prioritize your saving with these tips.
Beat Earnings, Stock Down, Rinse and Repeat
Not a good trend.
Nibbles Here and There at Forest Labs
Forest Laboratories banks on its usual strategy to offset generic-drug threats.
Thursday's Top Stories in Two Minutes
Google and Microsoft intensify their rivalry, China posts more impressive numbers while the U.S. faces losing its risk-free status, and more earnings than you can shake a fist at.
Double-Digit Growth in a Recession
Virus-killing Gilead gets it done.